PVSRIPO in Recurrent Malignant Glioma

Malignant Glioma Clinical Trial

Official title:

A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in Recurrent WHO Grade IV Malignant Glioma Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02986178
• Other study ID #: Pro00077024
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 1, 2017
• Est. completion date: March 2024

Study information

• Verified date: September 2023
• Source: Istari Oncology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.

Description:

This is a Phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of PVSRIPO in recurrent WHO grade IV malignant glioma.

Patients will be administered PVSRIPO intratumorally via convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. Retreatment with PVSRIPO is allowed, provided retreatment eligibility criteria are met.

All patients who receive PVSRIPO treatment will be included in efficacy and safety analyses.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 122
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA SUMMARY:

1. Patients must have a recurrent (first or second recurrence only, including this recurrence; transformation from a lower grade tumor to a WHO grade IV malignant glioma will be considered a first recurrence) supratentorial WHO grade IV malignant glioma based on imaging studies with measurable disease (a minimum measurement of 1 cm and maximum of 5.5 cm of contrast-enhancing tumor) with prior histopathology consistent with a WHO grade IV malignant glioma confirmed by the site's neuropathologist or the neuropathologist's designate.

2. Male patients who are sexually active are eligible if he and/or his partner(s) meets the criteria outlined in the protocol. Female subjects are eligible if he and/or his partner(s) meets the criteria outlined in the protocol.

3. Age = 18 years of age.

4. Karnofsky Performance Status (KPS) Score = 70%.

5. Prothrombin and Partial Thromboplastin Times = 1.2 x normal prior to biopsy.

6. Total bilirubin, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase = 2.5 x normal prior to biopsy.

7. Neutrophil count = 1000 prior to biopsy.

8. Hemoglobin = 9 prior to biopsy.

9. Platelet count = 100,000/µL unsupported is necessary for eligibility on study; however, because of risks of intracranial hemorrhage with catheter placement, platelet count = 125,000/µL is required for the patient to undergo biopsy and catheter insertion, which can be attained with the help of platelet transfusion.

10. Creatinine = 1.2 x normal range prior to biopsy.

11. Positive serum anti-PV titer prior to biopsy.

12. The patient must have received a boost immunization with trivalent inactivated IPOL™ (Sanofi-Pasteur) at least 1 week, but less than 6 weeks, prior to administration of the study agent.

13. At the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysis.

14. A signed IRB-approve informed consent form (ICF).

15. Able to undergo brain MRI with and without contrast.

EXCLUSION CRITERIA SUMMARY:

1. Females who are pregnant or breast-feeding.

2. Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons, their designate, and the reviewer designated by the sponsor.

3. Patients with severe, active co-morbidity, defined as in the protocol.

4. Patients with a previous history of neurological complications due to PV infection.

5. Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used.

6. Patients may not have received tumor treating fields (= 1 week), chemotherapy or bevacizumab = 4 weeks [except for nitrosourea and lomustine (= 6 weeks); metronomic dosed chemotherapy, such as daily temozolomide, etoposide or cyclophosphamide (= 1 week)] prior to starting the study drug.

7. Patients may not have received immunotherapy = 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy.

8. Patients may not be less than 12 weeks from radiation therapy of the brain, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation.

9. Prior to enrollment, has not completed all standard of care treatments, including surgical procedure and radiation therapy (at least 59Gy) as outlined in the protocol.

10. Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of multiple areas of active (growing) disease (active multifocal disease); tumors with contrast-enhancing tumor component crossing the midline (crossing the corpus callosum); extensive subependymal disease (tumor touching subependymal space is allowed); or extensive leptomeningeal disease (tumor touching leptomeninges is allowed).

11. Patients with undetectable anti-tetanus toxoid immunoglobulin G (IgG).

12. Patients with known history of agammaglobulinemia.

13. Patients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to admission for PVSRIPO infusion.

14. Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups).

15. Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin.

16. For patients randomized prior to V7, a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine.

17. Patients with active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months.

Related Conditions & MeSH terms

• Glioma
• Malignant Glioma

Intervention

Biological:
• PVSRIPO
A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Preston Robert Tisch Brain Tumor Center at Duke University	Durham	North Carolina
United States	Baptist MD Anderson Cancer Center	Jacksonville	Florida
United States	UCSF Neurological Surgery	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Istari Oncology, Inc.	Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Radiographic Response Rate	Assess objective anti-tumor response based on iRANO criteria.	24 months after initial PVSRIPO infusion and through study completion.
Primary	Objective Radiographic Response Rate	Assess objective anti-tumor response based on iRANO criteria.	36 months after initial PVSRIPO infusion and through study completion.
Primary	Duration of Objective Radiographic Response	Assess time of confirmed response to confirmed progressive disease/death.	24 months after initial PVSRIPO infusion and through study completion.
Primary	Duration of Objective Radiographic Response	Assess time of confirmed response to confirmed progressive disease/death.	36 months after initial PVSRIPO infusion and through study completion.
Secondary	Overall Survival	Overall Survival, relative to external control group(s)	24 and 36 months after initial PVSRIPO infusion and through study completion.
Secondary	Landmark Survival	Overall survival at 24 and 36 months and greater	24 and 36 months post-infusion and through study completion.
Secondary	Disease Control Rate Following PVSRIPO Infusion	The percentage of patients classified as non-progressive by radiographic response based on standard criteria.	24 and 36 months after initial PVSRIPO infusion and through study completion.
Secondary	Safety of PVSRIPO: proportion of patients who experience grade 3, 4, or 5 AEs	Within each cohort for those randomized prior to protocol version 7, as well as for those patients retreated with PVSRIPO, the proportion of patients who experience grade 3, 4, or 5 AEs that are possibly, probably, and definitely related to protocol treatment will be estimated.	While on study; average of 12 to 36 months after initial PVSRIPO infusion.

External Links

•   The Preston Robert Tisch Brain Tumor Center at Duke University